Magnesium 2000 postmarket evaluation: Guideline adherence and intraprocedural performance of a sirolimus-eluting resorbable magnesium scaffold
Highlights
- • Magmaris is a sirolimus-eluting bioresorbable magnesium scaffold CE-certified in 2016.
- • Intraprocedural data of 2000 cases from 356 centers worldwide are presented.
- • Magmaris was successfully deployed in 99% of cases.
- • The overall performance was rated as good or very good in 96% of cases.
- • Dual antiplatelet therapy was predominantly planned for 12 months.
Abstract
Background
The Magmaris bioresorbable magnesium scaffold was successfully tested in in-vitro and in clinical premarket studies. Subsequently the Magmaris postmarket program aimed to review intraprocedural data of at least 2000 patients to assess user preferences, guideline adherence and intraprocedural performance in clinical routine.